Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Jazz Pharmaceuticals is supported by a diversified and increasingly durable commercial base, with marketed products across neuroscience and oncology driving total sales growth from $2.4B in 2020 to an estimated $4.3B in 2026 and new products contributing about 65% of sales in 2022. The company’s core franchises are showing resilience and momentum, as Xywav continues to add patients even amid generic Xyrem competition, Epidiolex is still expanding through stronger execution and international opportunity, and oncology assets like Zepzelca, Rylaze, Vyxeos, Modeyso, and Ziihera provide multiple growth drivers with Q1 total revenues of $1.069B and Zepzelca revenue up 60% Y/Y to $101MM. Its outlook is further strengthened by recent product and regulatory progress, including Ziihera’s FDA approval in 1L HER2+ mGEA, the GW Pharmaceuticals acquisition that added Epidiolex, and management’s reiterated FY26 revenue guidance of $4.25B to $4.50B, which together suggest a business with meaningful expansion potential and improving portfolio breadth.

Jazz Pharmaceuticals is facing a negative fundamental setup because its sleep franchise is becoming more uncertain as payer dynamics are clarified, generic Xyrem launches continue, and the first orexin launch following TAK’s August PDUFA in NT1 could intensify competition against Xywav despite management’s near-term reassurance. While Xywav may remain durable, the company’s own outlook suggests pressure in narcolepsy could offset growth in IH, and even the modeled $1.7B peak annual Xywav sales assumes a balance that depends on continued execution in a market with rising competitive and reimbursement risk. Beyond sleep, the oncology portfolio still relies on a small number of programs with binary clinical and regulatory catalysts, including ongoing zanidatamab expansion efforts across BTC, GEA, CRC, NSCLC, and breast cancer, plus topline data expected in late 2027 or early 2028, leaving the investment case exposed to execution risk and concentrated future-readout uncertainty.